在HFrEF中重新考虑萨库比特里尔/瓦尔沙坦剂量策略:来自现实世界的实践的证据和影响 - 迷你评论
Kaiyuan Cen1,2,3, Juanyu Lin4,5, Fatimah Ahmedy6,7
1Cardiovascular Department, Guidong People's Hospital of Guangxi Zhuang Autonomous Region, Wuzhou, Guangxi, China. cky163163@163.com.
Journal of general internal medicine
|November 12, 2025
概括
萨库比特里尔/瓦尔萨坦在心力衰竭与减少喷射率 (HFrEF) 的现实世界使用表明,亚最大剂量可能是有效的. 建议以响应为指导的定位,而不是严格遵守目标剂量,以获得更好的患者结果.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 萨库比特里尔/瓦尔沙坦对心力衰竭与减少喷射率 (HFrEF) 管理至关重要.
- 萨库比特里尔/瓦尔萨坦在实际应用中,在最佳剂量方面面临着挑战.
- 指南建议目标剂量,但患者的并发症和耐受性往往会阻碍剂量升级.
研究的目的:
- 分析随机对照试验 (RCT) 与HFrEF中sacubitril/valsartan剂量的临床实践之间的差距.
- 为了评估在现实世界HFrEF患者群体中亚最大剂量萨库比特里尔/瓦尔萨坦的有效性.
- 倡导转向对萨库比特里尔/瓦尔萨坦治疗的响应导向定位策略.
主要方法:
- 非系统的叙事迷你回顾综合了关键的现实研究.
- 对全国范围的HFrEF队列 (n=3953) 的分析,检查剂量三位数和临床结果.
- 对一个多中心队列 (n=652) 的评估,比较不同剂量水平的萨库比特里尔/瓦尔萨坦的死亡率.
主要成果:
- 全国范围的HFrEF队列在平均剂量三位体中没有发现心力衰竭住院或全因死亡风险的显著差异.
- 一个多中心队列表明,当从非常低剂量升级到中等剂量的萨库比特里尔/瓦尔萨坦时,全因死亡率较低.
- 萨库比特里尔/瓦尔萨坦的增量益处在中间剂量之后似乎异质.
结论:
- 萨库比特里尔/瓦尔萨坦的亚最大剂量可能提供与HFrEF中目标剂量相比的临床益处.
- 以患者为中心,以反应为导向的定位策略,比严格遵守指南推剂量更可取.
- 以临床有效性和安全性为优先考虑的个性化药物治疗对于使用sacubitril/valsartan进行HFrEF管理至关重要.
相关概念视频
01:30Heart Failure V: Medical Management
207
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
207
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
902
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
902
01:22Heart Failure VI: Adjunct Therapies
243
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
243
01:22Heart Failure Drugs: Diuretics
779
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
779
01:28Mitral Regurgitation IV: Nursing Management
293
Mitral regurgitation (MR) is a condition where the mitral valve does not close properly, leading to the backward flow of blood from the left ventricle into the left atrium during systole. This condition can arise from various causes, including rheumatic fever, infective endocarditis, or degenerative valve disease. Effective nursing management is crucial to optimizing patient outcomes and involves comprehensive assessment and targeted interventions.Comprehensive Patient AssessmentA detailed...
293
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.3K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.3K